What is a stock summary page? Click here for an overview.
Business Description
MaxCyte Inc
NAICS : 334510
SIC : 3845
ISIN : US57777K1060
Description
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 8.57 | |||||
| Equity-to-Asset | 0.86 | |||||
| Debt-to-Equity | 0.09 | |||||
| Debt-to-EBITDA | -0.4 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 4.68 | |||||
| Beneish M-Score | -2.92 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 1.2 | |||||
| 3-Year EBITDA Growth Rate | -36.4 | |||||
| 3-Year EPS without NRI Growth Rate | -24.9 | |||||
| 3-Year FCF Growth Rate | -22.6 | |||||
| 3-Year Book Growth Rate | -7.6 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 24.76 | |||||
| 9-Day RSI | 27.73 | |||||
| 14-Day RSI | 29.76 | |||||
| 3-1 Month Momentum % | -16.95 | |||||
| 6-1 Month Momentum % | -11.37 | |||||
| 12-1 Month Momentum % | -20.6 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 10.88 | |||||
| Quick Ratio | 10.32 | |||||
| Cash Ratio | 9.79 | |||||
| Days Inventory | 563.86 | |||||
| Days Sales Outstanding | 48.47 | |||||
| Days Payable | 67.75 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.5 | |||||
| Shareholder Yield % | -0.34 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 81.66 | |||||
| Operating Margin % | -132.23 | |||||
| Net Margin % | -106.01 | |||||
| FCF Margin % | -75.75 | |||||
| ROE % | -18.6 | |||||
| ROA % | -16.15 | |||||
| ROIC % | -59.83 | |||||
| 3-Year ROIIC % | -61.2 | |||||
| ROC (Joel Greenblatt) % | -135.14 | |||||
| ROCE % | -21.45 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 7.89 | |||||
| PB Ratio | 1.48 | |||||
| Price-to-Tangible-Book | 1.48 | |||||
| EV-to-EBIT | -3.5 | |||||
| EV-to-EBITDA | -3.86 | |||||
| EV-to-Forward-EBITDA | -10.6 | |||||
| EV-to-Revenue | 4.64 | |||||
| EV-to-Forward-Revenue | 5.51 | |||||
| EV-to-FCF | -6.04 | |||||
| Price-to-GF-Value | 0.69 | |||||
| Price-to-Projected-FCF | 31.33 | |||||
| Price-to-Net-Current-Asset-Value | 2.19 | |||||
| Price-to-Net-Cash | 2.5 | |||||
| Earnings Yield (Greenblatt) % | -28.57 | |||||
| FCF Yield % | -9.14 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MXCT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
MaxCyte Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 38.628 | ||
| EPS (TTM) ($) | -0.39 | ||
| Beta | 1.3 | ||
| 3-Year Sharpe Ratio | -0.21 | ||
| 3-Year Sortino Ratio | -0.35 | ||
| Volatility % | 54.69 | ||
| 14-Day RSI | 29.76 | ||
| 14-Day ATR ($) | 0.218373 | ||
| 20-Day SMA ($) | 3.2445 | ||
| 12-1 Month Momentum % | -20.6 | ||
| 52-Week Range ($) | 2.715 - 5.26 | ||
| Shares Outstanding (Mil) | 106.03 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
MaxCyte Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
MaxCyte Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
MaxCyte Inc Frequently Asked Questions
What is MaxCyte Inc(MXCT)'s stock price today?
The current price of MXCT is $2.82. The 52 week high of MXCT is $5.26 and 52 week low is $2.72.
When is next earnings date of MaxCyte Inc(MXCT)?
The next earnings date of MaxCyte Inc(MXCT) is 2025-05-07 Est..
Does MaxCyte Inc(MXCT) pay dividends? If so, how much?
MaxCyte Inc(MXCT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers